155 related articles for article (PubMed ID: 38721105)
21. Impact of Metabolic Dysfunction Associated Fatty Liver Disease on the Prognosis of Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma Based on Propensity Score Matching Analysis.
Xue J; Wang QX; Xiao HM; Shi MJ; Xie YB; Li S; Lin M; Chi XL
Cancer Manag Res; 2022; 14():2193-2202. PubMed ID: 35859711
[TBL] [Abstract][Full Text] [Related]
22. Metabolic dysfunction-associated fatty liver disease increases the risk of complications after radical resection in patients with hepatocellular carcinoma.
Xiong KG; Ke KY; Kong JF; Lin TS; Lin QB; Lin S; Zhu YY
World J Surg Oncol; 2024 May; 22(1):117. PubMed ID: 38698475
[TBL] [Abstract][Full Text] [Related]
23. Temporal change in aetiology and clinical characteristics of hepatocellular carcinoma in a large cohort of patients in New South Wales, Australia.
Yeoh YKJ; Dore GJ; Lockart I; Danta M; Flynn C; Blackmore C; Levy MT; George J; Alavi M; Hajarizadeh B
Intern Med J; 2024 Apr; 54(4):602-612. PubMed ID: 37819787
[TBL] [Abstract][Full Text] [Related]
24. Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures.
Ezzat R; Eltabbakh M; El Kassas M
World J Gastrointest Oncol; 2021 Dec; 13(12):1919-1938. PubMed ID: 35070033
[TBL] [Abstract][Full Text] [Related]
25. Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study.
Johira Y; Nakahara T; Kinami T; Yamasaki S; Kosaka M; Shirane Y; Miura R; Murakami S; Yano S; Amioka K; Naruto K; Ando Y; Kosaka Y; Kodama K; Uchikawa S; Fujino H; Ono A; Murakami E; Okamoto W; Yamauchi M; Kawaoka T; Hayes CN; Tsuge M; Imamura M; Aikata H; Oka S
BMC Gastroenterol; 2023 Jun; 23(1):222. PubMed ID: 37380950
[TBL] [Abstract][Full Text] [Related]
26. Impact of MAFLD on the complications after hepatectomy in patients with HBV-related hepatocellular carcinoma.
Xiong KG; Lin TS; Kong JF; Lin QB; Chen LF; Ke KY
Medicine (Baltimore); 2023 Mar; 102(9):e33062. PubMed ID: 36862923
[TBL] [Abstract][Full Text] [Related]
27. Prevalence and clinical characteristics of patients with metabolic dysfunction-associated fatty liver disease with hepatitis C virus infection-a population-based study.
Attia D; Abdel Alem S; El-Akel W; Abdel-Razek W; Eslam M; Fouad Y; Waked I
Aliment Pharmacol Ther; 2022 Dec; 56(11-12):1581-1590. PubMed ID: 36168675
[TBL] [Abstract][Full Text] [Related]
28. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population.
Mittal S; Sada YH; El-Serag HB; Kanwal F; Duan Z; Temple S; May SB; Kramer JR; Richardson PA; Davila JA
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):594-601.e1. PubMed ID: 25148760
[TBL] [Abstract][Full Text] [Related]
29. The impact of concomitant hepatitis C virus infection on liver and cardiovascular risks in patients with metabolic-associated fatty liver disease.
Tsai PS; Cheng YM; Wang CC; Kao JH
Eur J Gastroenterol Hepatol; 2023 Nov; 35(11):1278-1283. PubMed ID: 37773778
[TBL] [Abstract][Full Text] [Related]
30. Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: a systematic review and meta-analysis.
Lehman EM; Wilson ML
Int J Cancer; 2009 Feb; 124(3):690-7. PubMed ID: 18973270
[TBL] [Abstract][Full Text] [Related]
31. Improving survival in patients with hepatocellular carcinoma related to chronic hepatitis C and B but not in those related to non-alcoholic steatohepatitis or alcoholic liver disease: a 20-year experience from a national programme.
Hassan I; Gane E
Intern Med J; 2019 Nov; 49(11):1405-1411. PubMed ID: 30908822
[TBL] [Abstract][Full Text] [Related]
32. Hepatocellular carcinoma in Egyptians with and without a history of hepatitis B virus infection: association with hepatitis C virus (HCV) infection but not with (HCV) RNA level.
Yates SC; Hafez M; Beld M; Lukashov VV; Hassan Z; Carboni G; Khaled H; McMorrow M; Attia M; Goudsmit J
Am J Trop Med Hyg; 1999 Apr; 60(4):714-20. PubMed ID: 10348253
[TBL] [Abstract][Full Text] [Related]
33. Increased prevalence but decreased survival of nonviral hepatocellular carcinoma compared to viral hepatocellular carcinoma in recent ten years.
Chen TC; Hsiao SW; Chen YY; Yen HH; Su WW; Hsu YC; Huang SP; Su PY
Sci Rep; 2024 Apr; 14(1):9068. PubMed ID: 38643245
[TBL] [Abstract][Full Text] [Related]
34. Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C.
Hsu PY; Hsu CT; Yeh ML; Huang CF; Huang CI; Liang PC; Lin YH; Hsieh MY; Wei YJ; Hsieh MH; Dai CY; Lin ZY; Chen SC; Huang JF; Yu ML; Chuang WL
Dig Dis Sci; 2020 Jul; 65(7):2120-2129. PubMed ID: 31722058
[TBL] [Abstract][Full Text] [Related]
35. The beneficial impact of metabolic dysfunction-associated fatty liver disease on lenvatinib treatment in patients with non-viral hepatocellular carcinoma.
Shimose S; Hiraoka A; Casadei-Gardini A; Tsutsumi T; Nakano D; Iwamoto H; Tada F; Rimini M; Tanaka M; Torimura T; Suga H; Ohama H; Burgio V; Niizeki T; Moriyama E; Suzuki H; Shirono T; Noda Y; Kamachi N; Nakano M; Kuromatsu R; Koga H; Kawaguchi T
Hepatol Res; 2023 Feb; 53(2):104-115. PubMed ID: 36149726
[TBL] [Abstract][Full Text] [Related]
36. Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Viral Hepatitis: The Interlink.
Fernandez CJ; Alkhalifah M; Afsar H; Pappachan JM
Pathogens; 2024 Jan; 13(1):. PubMed ID: 38251375
[TBL] [Abstract][Full Text] [Related]
37. Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular Carcinoma.
Chen VL; Yeh ML; Yang JD; Leong J; Huang DQ; Toyoda H; Chen YL; Guy J; Maeda M; Tsai PC; Huang CF; Yasuda S; Le AK; Dang H; Giama NH; Ali HA; Zhang N; Wang X; Jun DW; Tseng CH; Hsu YC; Huang JF; Dai CY; Chuang WL; Zhu Q; Dan YY; Schwartz M; Roberts LR; Yu ML; Nguyen MH
Hepatol Commun; 2021 Jan; 5(1):122-132. PubMed ID: 33437906
[TBL] [Abstract][Full Text] [Related]
38. Incidence of hepatocellular carcinoma in a community-based Taiwanese population without chronic HBV/HCV infection.
Wu HC; Jeng WJ; Pan MH; Hsieh YC; Lu SN; Chen CJ; Yang HI
JHEP Rep; 2022 Feb; 4(2):100410. PubMed ID: 35079699
[TBL] [Abstract][Full Text] [Related]
39. Genetic variants associated with the progression of hepatocellular carcinoma in hepatitis C Egyptian patients.
Motawi TK; Shaker OG; Ismail MF; Sayed NH
Gene; 2013 Sep; 527(2):516-20. PubMed ID: 23845776
[TBL] [Abstract][Full Text] [Related]
40. Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative Resection.
Lin YP; Lin SH; Wang CC; Lin CC; Chen DW; Chuang CH; Huang PY; Hung CH; Yang SY; Cho WR; Chen YS; Tsai MC
J Pers Med; 2021 Jul; 11(8):. PubMed ID: 34442328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
